Simple systemic index associated with oxaliplatin‐induced liver damage can be a novel biomarker to predict prognosis after resection of colorectal liver metastasis

Shimagaki, Tomonari; Sugimachi, Keizō; Mano, Yohei; Onishi, Emi; Iguchi, Tomohiro; Uehara, Hideo; Shimada, Masahiko; Yamamoto, Manabu; Morita, Masaru; Toh, Yasushi

doi:10.1002/ags3.12580

Cited by 3 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some studies, the development of sinusoidal obstruction syndrome (SOS) has been shown in patients treated with oxaliplatin-containing regimens [6][7][8]. In another study by Ward et al, surgery-confirmed SOS was found in 24 of 60 patients who received neo-adjuvant oxaliplatin-based chemotherapy for over 12 weeks [9][10].…”

Section: Discussionmentioning

confidence: 99%

Factors contributing to survival in hepatic dysfunction due to colorectal cancer

2022

View full text Add to dashboard Cite

Introduction/Objective. Colorectal Cancer(CRC) is currently the third most common cancer in incidence in the United States and accounts for about 8,5% of all cancer related deaths. Our study aimed to determine the parameters that contribute to the survival of CRC patients with hepatic dysfunction, attention to the positive effects on survival when the most appropriate clinical approaches. Methods. Patients with CRC, diagnosed with hepatic dysfunction, and who were followed up in our inpatient service in the last two years were included in our study. Survival rates were analyzed starting from after the development of hepatic failure. Results. A total of 57 patients were included in the study, 44 (77.2%) were colon carcinoma, and 13 (22.8%) were rectal carcinoma patients, and 14 (24.56%) were female. Bile Duct Dilatation (BD) was detected in 19 (33%) of 57 patients with imaging methods. The median OS was calculated as 4.0 vs. 1.4 months in patients with BD compared to patients without dilatation (p < 0.001). Survival times were significantly higher in patients with biliary tract dilatation compared to those without dilatation, and in patients without renal failure compared to those with renal failure. Conclusion. In cancer patients with hepatic dysfunction, those with additional renal failure had shorter survival times and a worse prognosis. The longer survival of patients with bile duct dilatation was attributed to the optimal timing of the Percutaneous Transhepatic Cholangiography (PTC) insertion, close clinical and inflammation marker follow-ups, and early prevention of external biliary drainage, therefore preventing a possible septic complication early on.

show abstract